Knight Therapeutics Inc. Acquires Orphan Canada Inc. and Expands Business Development Capacity
MONTREAL, QUEBEC–(Marketwired – Sept. 2, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an asset purchase agreement with Orphan Canada Inc. (“Orphan”) related to the Canadian rights for ATryn® and PHOTOFRIN® (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions. […]
Knight Expands Team
MONTREAL, QUEBEC–(Marketwired – Aug. 26, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today (1) the appointment of Amal Khouri to the position of Vice President of Business Development and (2) the appointment of Sylvie Tendler to Knight's Board of Directors. “Both Amal and Sylvie are proven pharmaceutical executives and expand our capacity to secure […]
Knight Reports Second Quarter 2014 Results
MONTREAL, QUEBEC–(Marketwired – Aug. 14, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) today reported its financial results for the quarter ended June 30, 2014. 2nd Quarter 2014 Highlights During the second quarter of 2014: On April 10, 2014, Knight completed a private placement of Additional Special Warrants for aggregate proceeds of $180,075,000. On April 17, […]
Knight Therapeutics Inc. Hires Advisor to Sell Its Priority Review Voucher
MONTREAL, CANADA–(Marketwired – Aug. 12, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an arrangement with a global investment banking firm to sell its neglected tropical disease Priority Review Voucher (“PRV”). The arrangement is effective August 18, 2014. Developed by the U.S. FDA […]
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement to Support the Acquisition of Apicore
MONTREAL, CANADA–(Marketwired – July 3, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement to support the acquisition of two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, “Apicore”) will be wholly owned operating subsidiaries. […]
Knight Therapeutics Inc. Invests in Sectoral Asset Management Inc. for Preferred Access to Canadian Product Rights
MONTREAL, QUEBEC–(Marketwired – June 26, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a letter of agreement with Sectoral Asset Management Inc. (“Sectoral”) to invest USD$13 million into its New Emerging Medical Opportunities Funds II, Ltd. (“NEMO II”). In exchange for Knight's investment […]
Knight Therapeutics Inc. and Origin Biomed Inc. Sign Secured Debt Financing Agreement
MONTREAL, CANADA–(Marketwired – June 25, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement with privately-held Origin Biomed Inc. (“Origin”), a company dedicated to the worldwide commercialization of the Neuragen® and Bionica brands. The $850,000 Canadian secured loan issued by […]
Knight Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto
MONTREAL, CANADA–(Marketwired – June 17, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday June 18, 2014 at 11:30 am ET at the […]
Knight Reports First Quarter 2014 Results
MONTREAL, QUEBEC–(Marketwired – May 28, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) today reported its financial results for the quarter ended March 31, 2014. 1st Quarter 2014 Highlights Listed on TSX-V on February 28, 2014 and began trading on TSX-V under the ticker symbol GUD.V on March 3, 2014. Entered into and completed a private […]
Knight Therapeutics Engages Genesys Capital Management to Assist with Business Development
MONTREAL, CANADA–(Marketwired – May 1, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) announced today that Genesys Capital Management Inc. (“Genesys”) has been engaged to assist Knight with its business development efforts. The mandate includes lending money on a secured basis to emerging biotechnology and specialty pharmaceutical companies in order to gain access to innovative products […]
